Format

Send to

Choose Destination
See comment in PubMed Commons below
J Infect Dis. 2013 Apr 15;207(8):1216-20. doi: 10.1093/infdis/jit017. Epub 2013 Jan 11.

Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe.

Collaborators (299)

Giacometti A, Butini L, del Gobbo R, Menzo S, Tacconi D, Corbelli G, Zanussi S, Monno L, Punzi G, Maggiolo F, Callegaro A, Calza L, Pristerà R, Turconi P, Mandas A, Tini S, Zoncada A, Paolini E, Amadio G, Sighinolfi L, Zuccati G, Morfini M, Manetti R, Corsi P, Galli L, Di Pietro M, Bartalesi F, Colao G, Tosti A, Di Biagio A, Setti M, Bruzzone B, Penco G, Trezzi M, Orani A, Pardelli R, De Gennaro M, Chiodera A, Scalzini A, Palvarini L, Almi P, Todaro G, Monforte Ad, Cicconi P, Rusconi S, Gismondo MR, Gismondo MR, Micheli V, Biondi ML, Gianotti N, Capetti A, Meraviglia P, Boeri E, Mussini C, Pecorari M, Soria A, Vecchi L, Santirocchi M, Brustia D, Ravanini P, Dal Bello F, Romano N, Mancuso S, Calzetti C, Maserati R, Filice G, Baldanti F, Francisci D, Parruti G, Polilli E, Sacchini D, Martinelli C, Consolini R, Vatteroni L, Vivarelli A, Dionisio D, Nerli A, Lenzi L, Magnani G, Ortolani P, Andreoni M, Palamara G, Fimiani C, Palmisano L, De Luca A, Fadda G, Vullo V, Turriziani O, Montano M, Cenderello G, Gonnelli A, Zazzi M, Palumbo M, Ghisetti V, Bonora S, Delle Foglie P, Rossi C, Grossi P, Seminari E, Poletti F, Mondino V, Malena M, Lattuada E, Lengauer T, Thielen A, Däumer M, Hoffmann D, Kaiser R, Schülter E, Müller C, Oette M, Reuter S, Esser S, Fätkenheuer G, Rockstroh J, van de Vijver DA, Incardona F, Rosen-Zvi M, Lengauer T, Camacho R, Clotet B, Ruiz i Garcia B, Vilasarau i Salat J, Font de Rubinat I, Plasència i Taradach A, Casabona i Barbara J, Arguelagués i Vidal E, Juárez RB, Gómez i Clarés M, Gatnau JL, Planas i Herrera E, Gelabert LR, Melia SM, Virosque MC, Arqué i Ferrer Mt, Veiga i Lluch A, Thalme A, Svedhem V, Bratt G, Gargiulo F, Manca N, Paraninfo G, Quiros-Roldan E, Castelnuovo F, Vandamme AM, Van Laethem K, Van Wijngaerden E, Ainsworth J, Anderson J, Babiker A, Chadwick D, Delpech V, Dunn D, Fisher M, Gazzard B, Gilson R, Gompels M, Hay P, Hill T, Johnson M, Kegg S, Leen C, Nelson M, Orkin C, Palfreeman A, Phillips A, Pillay D, Post F, Sabin C, Sachikonye M, Schwenk A, Walsh J, Hill T, Huntington S, Josie S, Phillips A, Sabin C, Thornton A, Dunn D, Glabay A, Orkin C, Lynch J, Hand J, Fisher M, Perry N, Tilbury S, Churchill D, Gazzard B, Nelson M, Waxman M, Asboe D, Mandalia S, Delpech V, Anderson J, Munshi S, Awosika D, Post F, Korat H, Taylor C, Gleisner Z, Ibrahim F, Campbell L, Gilson R, Brima N, Williams I, Schwenk A, Ainsworth J, Wood C, Miller S, Johnson M, Youle M, Lampe F, Smith C, Grabowska H, Chaloner C, Puradiredja D, Walsh J, Mackie N, Winston A, Weber J, Ramzan F, Leen C, Wilson A, Gompels M, Allan S, Palfreeman A, Moore A, Fox L, Chadwick D, Baillie K, Kegg S, Main P, Allan S, Hay P, Dhillon M, Martin F, Douglas S, Anderson J, Asboe D, Pozniak A, Cameron S, Chadwick D, Churchill D, Clark D, Collins S, Walker C, Delpech V, Pillay D, Lazarus L, Dunn D, Dolling D, Fearnhill E, Castro H, Porter K, Coughlin K, Dolling D, Zuckerman M, Geretti AM, Booth C, Goldberg D, Gompels M, Hale A, Kaye S, Kellam P, Leigh-Brown A, Mackie N, Orkin C, Pillay D, Phillips A, Sabin C, Smit E, Templeton K, Tilston P, Tong W, Thomas S, Williams I, Zhang H, Zhang H, Clark D, Ushiro-Lumb I, Oliver T, Bibby D, Mitchell S, Smit E, Mbisa T, Wildfire A, Tandy R, Shepherd J, Chadwick D, MacLean A, Tong W, Bennett D, Hopkins M, Tilston P, Booth C, Garcia-Diaz A, Kaye S, Kirk S, Sloot PM.

Author information

1
Catholic University of the Sacred Heart, Rome, Italy. deluca.andrea@fastwebnet.it

Abstract

HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20 323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis.

PMID:
23315324
DOI:
10.1093/infdis/jit017
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center